Skip to main content

Table 1 Patient and procedural characteristics

From: Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds

 

All patients (n = 657)

Patients with diabetes (n = 138)

Patients without diabetes (n = 519)

P-value

Age (years)

63 ± 12

65 ± 11

62 ± 12

0.015

Male

519/657 (79.0%)

107/138 (77.5%)

412/519 (79.4%)

0.722

Hypertension

478/657 (72.8%)

117/138 (84.8%)

361/519 (69.6%)

< 0.001

Smoking

273/657 (41.6%)

48/138 (34.8%)

225/519 (43.3%)

0.086

Family History

138/657 (21.0%)

21/138 (15.2%)

117/519 (22.5%)

0.078

Hyperlipidemia

268/657 (40.8%)

76/138 (55.1%)

192/519 (37.0%)

< 0.001

Prior CABG

14/657 (2.1%)

5/138 (3.6%)

9/519 (1.7%)

0.186

Prior PCI

181/657 (27.5%)

48/138 (34.8%)

133/519 (25.6%)

0.042

Prior stroke/TIA

27/657 (4.1%)

11/138 (8.0%)

16/519 (3.1%)

0.020

eGFR (ml/min)

83 ± 23

76 ± 25

84 ± 22

< 0.001

LVEF (%)

52 ± 8

53 ± 7

52 ± 9

0.590

Silent/stable angina

219/657 (33.3%)

56/138 (40.6%)

163/519 (31.4%)

0.054

Unstable Angina

78/657 (11.9%)

20/138 (14.5%)

58/519 (11.1%)

0.356

NSTEMI

191/657 (29.1%)

33/138 (23.9%)

158/519 (30.4%)

0.163

STEMI

166/657 (25.3%)

28/138 (20.3%)

138/519 (26.6%)

0.161

Lesion characteristics

 LAD treated with BRS

301/657 (45.8%)

68/138 (49.3%)

233/519 (44.9%)

0.411

 LCX treated with BRS

161/657 (24.4%)

36/138(26.1%)

125/519(24.1%)

0.708

 RCA treated with BRS

194/657 (29.7%)

34/138 (24.6%)

160/519 (30.8%)

0.190

 Graft treated with BRS

1/657 (0.2%)

0/138 (0%)

1/519 (0.2%)

1

 Ostial lesion

53/657 (8.1%)

10/138 (7.2%)

43/519 (8.3%)

0.824

 CTO

11/657(1.7%)

2/138 (1.4%)

15/519 (2.9%)

0.546

Bifurcation

82/657(12.5%)

13/138(9.4%)

69/519(13.3%)

0.281

 At least one lesion type B2 or C

297/657 (45.2%)

62/138 (44.9%)

235/519 (45.3%)

0.982

Procedural characteristics

 Number of vessels treated with BVS

1.2 ± 0.4

1.2 ± 0.5

1.1 ± 0.4

0.095

 Number of BRS per patient

1.4 ± 0.8

1.5 ± 0.9

1.4 ± 0.8

0.181

vHybrid BRS + DES

330/657(50.2%)

56/138(40.6%)

274/519(52.8%)

0.014

 Predilatation

653/657(99.4%)

136/138(98.6%)

517/519(99.6%)

0.196

 Diameter predilatation ballon (mm)

2.80 ± 0.37

2.83 ± 0.36

2.80 ± 0.37

0.367

Minimum stent diameter per patient (mm)

2.97 ± 0.38

2.96 ± 0.36

2.98 ± 0.38

0.572

 Total implanted length per patient (mm)

27.5 ± 18.9

29.0 ± 19.4

27.2 ± 18.8

0.324

 Postdilatation

306/657(46.6%)

71/138(51.4%)

235/519(45.3%)

0.232

 Preprocedural RVD, mm

2.93 ± 0.67

2.91 ± 0.77

2.94 ± 0.65

0.728

 Preprocedural MLD, mm

0.61 ± 0.51

0.71 ± 0.41

0.58 ± 0.54

0.026

 % stenosis per lesion

78.2 ± 17.9

74.6 ± 13.6

79.4 ± 18.8

0.014

Angiographic Outcome

 Postprocedural RVD, mm

3.0 ± 0.5

3.0 ± 0.4

3.0 ± 0.5

0.760

vPostprocedural MLD, mm

2.5 ± 0.5

2.5 ± 0.5

2.5 ± 0.5

0.135

 Residual stenosis per lesion (%)

14.5 ± 10.8

16.7 ± 13.2

13.7 ± 9.9

0.018

 MLD/nominal BRS diameter

0.84 ± 0.13

0.82 ± 0.16

0.85 ± 0.13

0.101

 Lumen Gain, mm

1.63 ± 0.62

1.61 ± 0.61

1.68 ± 0.56

0.382

 Optimal implantation technique

311/657 (47.3%)

74/138 (53.6%)

237/519 (45.7%)

0.117

 Overlap

74/657 (11.3%)

12/138 (8.7%)

62/519 (11.9%)

0.357

 Clopidogrel

200/657 (30.4%)

51/138 (37.0%)

149/519 (28.7%)

0.077

 Prasugrel

324/657 (49.3%)

67/138 (48.6%)

257/519 (49.5%)

0.915

 Ticagrelor

132/657 (20.1%)

19/138 (13.8%)

113/519 (21.8%)

0.076

  1. P < 0.05 as statistically significant are in bold